Últimas noticias sobre HealthStream (NASDAQ:HSTM) Bolsa

HealthStream

HealthStream Inc provides workforce and provider solutions for healthcare organizations. Its reportable segments include Workforce Solutions and Provider Solutions. Workforce development solutions consist of SaaS, subscription-based products that are used by healthcare organizations. Its Provider Solutions products offer healthcare organizations software applications for administering and tracking provider credentialing, privileging, call center and enrollment activities. The company generates a majority of its revenue from Subscription Services.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ALUR

ASST

AVBP

CNOB

DWTX

HSTM

IPHA

LGTY

MDXG

The Marygold Companies, Inc. Common Stock

MGLD

MULN

ONCO

PXLW

RMBI

TVGN

VINC

Explora los movimientos más destacados del pre-mercado, incluyendo el aumento del 23% en Logility y más sorpresas.

Acciones de Logility Supply Chain (LGTY) suben un 23%; 20 acciones que se mueven en el premercado de EE.UU.

HealthStream Inc

Shares of Logility Supply Chain Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGTY#NASDAQ">LGTY</a>) rose sharply in today's pre-market trading after Aptean announced an agreement to acquire Logility in a $14.30-per-share <a href="https://www.benzinga.com/quote/LGTY">all-cash deal</a>.
Logility Supply Chain Solutions shares jumped 23.2% to $13.95 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>HWH International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWH#NASDAQ">HWH</a>) gained 80.5% to $0.5194 in pre-market trading. On Jan. 23, HWH International received a notice from the Nasdaq Stock Market, informing the company that it has demonstrated compliance with Nasdaq&#8217;s Listing Rule 5550(b)(1).</li>
<li>Tevogen Bio Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) gained 65.2% to $2.23 in pre-market trading after the company expanded collaboration with Microsoft to advance AI-Powered PredicTcell Technology on Azure.</li>
<li>Onconetix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) rose 30.3% to $0.6151 in pre-market trading.</li>
<li>Innate Pharma S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) gained 18.5% to $2.04 in pre-market trading. Innate Pharma dosed first patient in Phase 1 study of IPH4502, a targeted ADC for difficult-to-treat advanced solid tumors.</li>
<li>Pixelworks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXLW#NASDAQ">PXLW</a>) gained 14.5% to $1.010 in pre-market trading.</li>
<li>Asset Entities Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>) rose 14.2% to $1.28 in pre-market trading after gaining more than 5% on Friday.</li>
<li>Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) gained 12.2% to $0.4946 in pre-market trading after the company reported FY24 revenue of $1.09 million up from $366K in the year-ago period.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) rose 11.2% to $12.00 in pre-market trading after jumping 13% on Friday.</li>
<li>ConnectOne Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNOB#NASDAQ">CNOB</a>) gained 7.6% to $24.99 in pre-market trading. ConnectOne Bancorp will release results for the fourth quarter, before the opening bell on Thursday, Jan. 30.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>MiMedx Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>) shares fell 42% to $5.10 in pre-market trading.</li>
<li>The Marygold Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGLD#NASDAQ">MGLD</a>) shares fell 27.4% to $1.14 in pre-market trading. Marygold Companies priced its $2.25 million public offering of 2,050,000 common stock at $1.10 per share.</li>
<li>Aclarion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) shares tumbled 27.1% to $0.0400 in pre-market trading after jumping more than 27% on Friday. Aclarion recently announced a $14.4 million public offering of common stock and warrants.</li>
<li>MBX Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBX#NASDAQ">MBX</a>) dipped 25.3% to $8.03 in pre-market trading after falling 8% on Friday.</li>
<li>Allurion Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) declined 19.9% to $6.96 in pre-market trading. Allurion Technologies shares jumped 135% on Friday after the company announced its intention to initiate a clinical study combining its Allurion program with GLP-1 agonists to improve muscle mass and overall body composition.</li>
<li>Dogwood Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) fell 19.3% to $9.20 in today's pre-market trading after dipping around 15% on Friday.</li>
<li>HealthStream, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) shares dipped 16.1% to $27.01 in pre-market trading.</li>
<li>ArriVent BioPharma, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>) fell 14.1% to $23.47 in pre-market trading. ArriVent BioPharma, last week, entered into exclusive license with Lepu Biopharma for MRG007, an antibody drug conjugate for treatment of gastrointestinal cancers.</li>
<li>Richmond Mutual Bancorporation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBI#NASDAQ">RMBI</a>) fell 12.6% to $12.00 in pre-market trading. Richmond Mutual Bancorp, last week, posted fourth-quarter earnings of 25 cents per share, up from 19 cents per share in the year-ago period.</li>
<li>Vincerx Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) fell 10.6% to $0.0930 in pre-market trading. Vincerx Pharma filed for mixed shelf offering of up to $100 million.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/01/43189390/top-3-materials-stocks-that-may-fall-off-a-cliff-in-january">Top 3 Materials Stocks That May Fall Off A Cliff In January</a></li>
</ul>

Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket

Barclays maintains HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) with a Overweight and raises the price target from $32 to $34.

Price Target

Analyst Ratings

Barclays Maintains Overweight on HealthStream, Raises Price Target to $34

Canaccord Genuity analyst Richard Close maintains HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) with a Hold and raises the price target from $28 to $29.

Canaccord Genuity Maintains Hold on HealthStream, Raises Price Target to $29

HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.12 by 58.33 percent. This is a 46.15 percent increase over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $73.09 million which missed the analyst consensus estimate of $73.53 million by 0.59 percent. This is a 3.92 percent increase over sales of $70.34 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

HealthStream Q3 EPS $0.19 Beats $0.12 Estimate, Sales $73.09M Miss $73.53M Estimate

HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) lowers FY2024 sales outlook from $292.00 million-296.00 million to $290.00 million-292.00 million.

Guidance

HealthStream Lowers FY2024 Sales Guidance from $292.00M-296.00M to $290.00M-292.00M (Est. 292.373M)

HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) will release its quarterly earnings report on Monday, 2024-10-21. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate HealthStream to report an earnings per share (EPS) of $0.12.
Anticipation surrounds HealthStream's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.04, leading to a 4.04% drop in the share price on the subsequent day.
Here's a look at HealthStream's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.12</td>
<td>0.11</td>
<td>0.10</td>
<td>0.09</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.16</td>
<td>0.17</td>
<td>0.15</td>
<td>0.13</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>10.0%</td>
<td>-2.0%</td>
<td>15.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1729275952_0.png" alt="eps graph" />
<h3>Performance of HealthStream Shares</h3>
Shares of HealthStream were trading at $28.93 as of October 17. Over the last 52-week period, shares are up 31.2%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Opinions on HealthStream</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on HealthStream.
HealthStream has received a total of 1 ratings from analysts, with the consensus rating as Neutral. With an average one-year price target of $28.0, the consensus suggests a potential 3.21% downside.
<h3>Understanding Analyst Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Simulations Plus, Phreesia and Definitive Healthcare, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Simulations Plus received a Outperform consensus from analysts, with an average 1-year price target of $47.0, implying a potential 62.46% upside.</li>
<li>The prevailing sentiment among analysts is an Buy trajectory for Phreesia, with an average 1-year price target of $29.4, implying a potential 1.62% upside.</li>
<li>Definitive Healthcare is maintaining an Neutral status according to analysts, with an average 1-year price target of $5.61, indicating a potential 80.61% downside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
Within the peer analysis summary, vital metrics for Simulations Plus, Phreesia and Definitive Healthcare are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>HealthStream</td>
<td>Neutral</td>
<td>3.41%</td>
<td>$47.82M</td>
<td>1.20%</td>
</tr>
<tr>
<td>Simulations Plus</td>
<td>Outperform</td>
<td>14.23%</td>
<td>$13.26M</td>
<td>1.75%</td>
</tr>
<tr>
<td>Phreesia</td>
<td>Buy</td>
<td>18.97%</td>
<td>$69.30M</td>
<td>-7.15%</td>
</tr>
<tr>
<td>Definitive Healthcare</td>
<td>Neutral</td>
<td>4.56%</td>
<td>$50.45M</td>
<td>-28.39%</td>
</tr>
</tbody>
</table>

Key Takeaway:
HealthStream ranks in the middle for consensus rating among its peers. It is at the bottom for revenue growth. In terms of gross profit, HealthStream is at the top among its peers. However, its return on equity is at the bottom compared to the others.
<h3>About HealthStream</h3>
HealthStream Inc provides workforce and provider solutions for healthcare organizations. Its reportable segments include Workforce Solutions and Provider Solutions. Workforce development solutions consist of SaaS, subscription-based products that are used by healthcare organizations. Its Provider Solutions products offer healthcare organizations software applications for administering and tracking provider credentialing, privileging, call center and enrollment activities. The company generates a majority of its revenue from Subscription Services.
<h3>HealthStream's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: HealthStream's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 3.41%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: HealthStream's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.82% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): HealthStream's ROE stands out, surpassing industry averages. With an impressive ROE of 1.2%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): HealthStream's ROA excels beyond industry benchmarks, reaching 0.82%. This signifies efficient management of assets and strong financial health.
Debt Management: HealthStream's debt-to-equity ratio is below the industry average at 0.05, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/HSTM/earnings">To track all earnings releases for HealthStream visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For HealthStream

HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) is preparing to release its quarterly earnings on Monday, 2024-10-21. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect HealthStream to report an earnings per share (EPS) of $0.12.
The market awaits HealthStream's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.04, which was followed by a 4.04% drop in the share price the next day.
Here's a look at HealthStream's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.12</td>
<td>0.11</td>
<td>0.10</td>
<td>0.09</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.16</td>
<td>0.17</td>
<td>0.15</td>
<td>0.13</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>10.0%</td>
<td>-2.0%</td>
<td>15.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1729267292_0.png" alt="eps graph" />
<h3>HealthStream Share Price Analysis</h3>
Shares of HealthStream were trading at $28.93 as of October 17. Over the last 52-week period, shares are up 30.86%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Perspectives on HealthStream</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on HealthStream.
HealthStream has received a total of 1 ratings from analysts, with the consensus rating as Neutral. With an average one-year price target of $28.0, the consensus suggests a potential 3.21% downside.
<h3>Peer Ratings Overview</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Simulations Plus, Phreesia and Definitive Healthcare, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Simulations Plus received a Outperform consensus from analysts, with an average 1-year price target of $47.0, implying a potential 62.46% upside.</li>
<li>The prevailing sentiment among analysts is an Buy trajectory for Phreesia, with an average 1-year price target of $29.4, implying a potential 1.62% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Definitive Healthcare, with an average 1-year price target of $5.61, suggesting a potential 80.61% downside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
Within the peer analysis summary, vital metrics for Simulations Plus, Phreesia and Definitive Healthcare are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>HealthStream</td>
<td>Neutral</td>
<td>3.41%</td>
<td>$47.82M</td>
<td>1.20%</td>
</tr>
<tr>
<td>Simulations Plus</td>
<td>Outperform</td>
<td>14.23%</td>
<td>$13.26M</td>
<td>1.75%</td>
</tr>
<tr>
<td>Phreesia</td>
<td>Buy</td>
<td>18.97%</td>
<td>$69.30M</td>
<td>-7.15%</td>
</tr>
<tr>
<td>Definitive Healthcare</td>
<td>Neutral</td>
<td>4.56%</td>
<td>$50.45M</td>
<td>-28.39%</td>
</tr>
</tbody>
</table>

Key Takeaway:
HealthStream ranks in the middle for consensus rating among its peers. It is at the bottom for revenue growth. In terms of gross profit, HealthStream is at the top among its peers. However, its return on equity is at the bottom compared to the others.
<h3>All You Need to Know About HealthStream</h3>
HealthStream Inc provides workforce and provider solutions for healthcare organizations. Its reportable segments include Workforce Solutions and Provider Solutions. Workforce development solutions consist of SaaS, subscription-based products that are used by healthcare organizations. Its Provider Solutions products offer healthcare organizations software applications for administering and tracking provider credentialing, privileging, call center and enrollment activities. The company generates a majority of its revenue from Subscription Services.
<h3>HealthStream: Delving into Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining HealthStream's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 3.41% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: HealthStream's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.82% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): HealthStream's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.2%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): HealthStream's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.82% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.05.
<a href="https://www.benzinga.com/quote/HSTM/earnings">To track all earnings releases for HealthStream visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

An Overview of HealthStream's Earnings

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares rose 123.5% to $0.85 during Monday's pre-market session. The market value of their outstanding shares is at $144.7 million. </li>
<li>Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) shares increased by 67.19% to $3.16. The market value of their outstanding shares is at $165.4 million. </li>
<li>Longboard Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBPH#NASDAQ">LBPH</a>) stock rose 51.28% to $58.85. The market value of their outstanding shares is at $2.2 billion. </li>
<li>Immuron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRN#NASDAQ">IMRN</a>) shares rose 18.18% to $2.6. The company's market cap stands at $14.8 million. </li>
<li>Jasper Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) stock increased by 15.05% to $17.27. The market value of their outstanding shares is at $260.8 million. </li>
<li>Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) shares rose 13.86% to $2.3. The market value of their outstanding shares is at $67.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) shares declined by 78.5% to $0.32 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares fell 16.77% to $0.82. The market value of their outstanding shares is at $8.2 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) shares declined by 11.9% to $3.63. The company's market cap stands at $4.8 million. </li>
<li>HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) shares declined by 8.87% to $26.0. The market value of their outstanding shares is at $790.6 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) stock decreased by 7.74% to $0.37. The market value of their outstanding shares is at $1.0 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares declined by 7.65% to $0.43. The market value of their outstanding shares is at $2.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALPS ETF Trusthen & Steers Global Realty Majors ETF

IMRN

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

LBPH

MTEM

NIVF

RANI

VRPX

12 Health Care Stocks Moving In Monday's Pre-Market Session

Canaccord Genuity analyst Richard Close maintains HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) with a Hold and raises the price target from $27 to $28.

Canaccord Genuity Maintains Hold on HealthStream, Raises Price Target to $28

HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.12 by 33.33 percent. The company reported quarterly sales of $71.556 million which missed the analyst consensus estimate of $72.851 million by 1.78 percent. This is a 3.41 percent increase over sales of $69.198 million the same period last year.

HealthStream Q2 2024 Adj EPS $0.16 Beats $0.12 Estimate, Sales $71.556M Miss $72.851M Estimate

Shares of Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) fell sharply during Tuesday's session after the company reported worse-than-expected <a href="https://www.benzinga.com/news/earnings/24/04/38365860/nucor-shares-fall-after-worse-than-expected-q1-results">quarterly financial results</a>.
Nucor reported quarterly earnings of $3.46 per share which missed the analyst consensus estimate of $3.65. Quarterly sales came in at $8.14 billion, missing the analyst consensus estimate of $8.26 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Nucor shares tumbled 6.5% to $179.20 on Tuesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares jumped 100% to $0.2419 after the company announced that it has been chosen to supply its DriveMod Tuggers for industrial automation to John Deere&#8217;s operation in Dubuque, Iowa.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) shares climbed 50.4% to $0.0689 after falling 10% on Monday.</li>
<li>Oportun Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRT#NASDAQ">OPRT</a>) gained 46% to $3.29 after the company announced preliminary first-quarter total revenue above estimates.</li>
<li>Palisade Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) shares climbed 44.3% to $7.12 after the company entered a collaboration with Strand Life Sciences.</li>
<li>KULR Technology Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NASDAQ">KULR</a>) gained 27% to $0.5683 after the company announced it delivered on an immediate basis, a power cell battery deployment order for AI-enabled drone and advanced air mobility missions in Ukraine.</li>
<li>Smart for Life, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMFL#NASDAQ">SMFL</a>) climbed 20% to $5.22.</li>
<li>HWH International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWH#NASDAQ">HWH</a>) rose 19.5% to $1.5307 after declining 3% on Monday.</li>
<li>SolarMax Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXT#NASDAQ">SMXT</a>) gained 18.7% to $9.49.</li>
<li>Hibbett, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIBB#NASDAQ">HIBB</a>) rose 18.4% to $85.85 after the company agreed to be acquired by JD Sports Fashion for $87.50 per share in cash, in a $1.1 billion transaction.</li>
<li>SES AI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) gained 17.4% to $1.3499.</li>
<li>SolarMax Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXT#NASDAQ">SMXT</a>) rose 15.5% to $9.24.</li>
<li>FuelCell Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>) gained 15.5% to $0.9295.</li>
<li>Carmell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) climbed 15.2% to $2.20.</li>
<li>Azitra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#NYSE">AZTR</a>) shares gained 15% to $0.2244 after the company announced new preclinical data will be presented at the American Society of Gene and Cell Therapy meeting.</li>
<li>Virgin Galactic Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NASDAQ">SPCE</a>) jumped 14.4% to $0.8603.</li>
<li>9F Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFU#NASDAQ">JFU</a>) rose 14.3% to $3.29.</li>
<li>Canaan Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) gained 14% to $1.05. The company executives announced intentions to purchase at least $2 million of the company's common stock.</li>
<li>Cartesian Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) jumped 12.7% to $20.59 after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a $39 price target.</li>
<li>Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) gained 12.3% to $305.73 following first-quarter financial results.</li>
<li>Heron Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) climbed 11.6% to $2.89 after Capital One initiated coverage on the stock with an Overweight rating and $6 price target.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) gained 9.4% to $6.05.</li>
<li>Ryder System, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/R#NYSE">R</a>) rose 9% to $118.82 following better-than-expected quarterly earnings.</li>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) jumped 8.8% to $10.15.</li>
<li>HealthStream, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) surged 7.4% to $25.91 following upbeat quarterly results.</li>
<li>Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) shares rose 7% to $0.55 following upbeat quarterly results.</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) gained 6.2% to $62.20.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Abeona Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) fell 48.4% to $3.7950 after the company announced the FDA issued a Complete Response Letter in response to the company&#8217;s Biologics License Application for pz-cel for the treatment of patients with recessive dystrophic epidermolysis bullosa.</li>
<li>Greenwave Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) shares fell 44.6% to $0.0699. Greenwave Technology Solutions disclosed that it further strengthened its balance sheet by approximately $12 million.</li>
<li>Lichen China Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) fell 44.4% to $0.5450.</li>
<li>Tungray Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRSG#NASDAQ">TRSG</a>) shares declined 34.2% to $4.87 after gaining 24% on Monday.</li>
<li>Tian Ruixiang Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIRX#NASDAQ">TIRX</a>) fell 26.3% to $0.5091.</li>
<li>Moolec Science SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLEC#NASDAQ">MLEC</a>) fell 24.3% to $1.87. On April 22, Moolec Science said it received approval for its plant-grown animal proteins.</li>
<li>YY Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YYGH#NASDAQ">YYGH</a>) fell 22.4% to $2.25 after tumbling over 27% on Monday. The company, last week, priced its IPO at $4 per share.</li>
<li>Top Wealth Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWG#NASDAQ">TWG</a>) dipped 19.7% to $2.0899.</li>
<li>Comstock Holding Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHCI#NASDAQ">CHCI</a>) declined 18.8% to $6.44.</li>
<li>SuperCom Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCB#NASDAQ">SPCB</a>) dipped 18% to $0.2369. SuperCom recently reported better-than-expected quarterly results.</li>
<li>JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) declined 16.2% to $6.29 after the company reported first-quarter financial results and issued worse-than-expected Q2 and FY24 Revenue outlook.</li>
<li>MSCI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) declined 13% to $448.01 following first-quarter financial results.</li>
<li>LKQ Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKQ#NASDAQ">LKQ</a>) fell 12.6% to $42.78 after the company reported a first-quarter earnings miss and cut its FY24 outlook.</li>
<li>Simpson Manufacturing Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSD#NYSE">SSD</a>) dipped 11.7% to $163.40 following weak quarterly earnings.</li>
<li>Jaguar Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares fell 11.2% to $0.1598 after the company filed for a mixed shelf offering of up to $75 million.</li>
<li>Xerox Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRX#NASDAQ">XRX</a>) tumbled 11.1% to $14.60 after the company reported worse-than-expected first-quarter results and reiterated FY24 guidance.</li>
<li>T2 Biosystems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) declined 10.4% to $2.83 after gaining around 7% on Monday.</li>
<li>Sasol Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>) shares fell 10.1% to $7.13 after the company issued its production and sales performance metrics for the nine months ended 31 March, 2024.</li>
<li>Complete Solaria, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSLR#NASDAQ">CSLR</a>) fell 9.3% to $0.3530 after dipping around 14% on Monday.</li>
<li>Cleveland-Cliffs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) dipped 7.8% to $19.22 after the company&#8217;s reported worse-than-expected first-quarter financial results.</li>
<li>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) fell 7.1% to $0.77. Phio Pharmaceuticals shares jumped around 33% on Monday after the company announced that its intratumoral injection of murine PH-762 inhibited tumor growth in murine tumor models and may generate memory-specific T cells.</li>
<li>Calix, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) shares fell 4.1% to $28.34 after the company reported mixed first-quarter financial results and issued second-quarter guidance below estimates.</li>
</ul>
Read More: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38379861/bitcoin-surpasses-66-000-akash-network-core-among-top-gainers">Bitcoin Surpasses $66,000; Akash Network, Core Among Top Gainers</a>

Intraday Update

ABEO

AZTR

CALX

CDTX

CHCI

CSLR

CTCX

FCEL

GWAV

HIBB

HRTX

JAGX

JBLU

KULR

LICN

MESO

MLEC

MSCI

OPRT

PALI

PEGY

PHIO

RNAC

ROKU

SMFL

SMXT

SPCB

SPCE

SPOT

TIRX

TRSG

TTOO

YYGH

Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

WIIM

HealthStream shares are trading higher after the company reported better-than-expected Q1 financial results.

U.S. stocks were higher, with the Nasdaq Composite gaining over 200 points on Tuesday.
Shares of HealthStream, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) rose sharply during Tuesday's session following upbeat <a href="https://www.benzinga.com/quote/HSTM/earnings">quarterly results</a>.
HealthStream posted first-quarter GAAP earnings of 17 cents per share, beating market estimates of 11 cents per share. The company's quarterly sales came in at $72.760 million versus expectations of $71.883 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
HealthStream shares jumped 7.4% to $25.91 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>MMTec, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) shares gained 29% to $2.03.</li>
<li>Hibbett, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIBB#NASDAQ">HIBB</a>) shares climbed 18.4% to $85.85 after the company agreed to be acquired by JD Sports Fashion for $87.50 per share in cash, in a $1.1 billion transaction.</li>
<li>SolarMax Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXT#NASDAQ">SMXT</a>) shares jumped 15.5% to $9.24.</li>
<li>FuelCell Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>) rose 15.5% to $0.9295.</li>
<li>SES AI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) climbed 14.2% to $1.3150.</li>
<li>Virgin Galactic Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NASDAQ">SPCE</a>) gained 14.4% to $0.8603.</li>
<li>Critical Metals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRML#NASDAQ">CRML</a>) rose 14.2% to $10.30. Critical Metals named Tony Sage as Chief Executive Officer.</li>
<li>Cartesian Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) surged 12.7% to $20.59 after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a $39 price target.</li>
<li>Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) shares jumped 12.3% to $305.73 following first-quarter financial results.</li>
<li>Heron Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) gained 11.6% to $2.89 after Capital One initiated coverage on the stock with an Overweight rating and $6 price target.</li>
<li>Sweetgreen, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) rose 10.3% to $22.42.</li>
<li>Repligen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) climbed 9.6% to $172.59 as life sciences stocks gained following strong earnings from Danaher.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) surged 9.4% to $6.05.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) rose 9.2% to $783.26.</li>
<li>Ryder System, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/R#NYSE">R</a>) climbed 9% to $118.82 following better-than-expected quarterly earnings.</li>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) rose 8.8% to $10.15.</li>
<li>Lifezone Metals Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LZM#NYSE">LZM</a>) gained 8.4% to $7.26.</li>
<li>Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) rose 8.1% to $10.86.</li>
<li>Marathon Digital Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) surged 8.1% to $19.00.</li>
<li>BeiGene, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGNE#NASDAQ">BGNE</a>) rose 7.4% to $140.70 after the European Commission approved Tislelizumab for non-small cell lung cancer across three indications, including first- and second-line use.</li>
<li>Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) rose 7% to $252.49 following better-than-expected first-quarter financial results.</li>
<li>e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) gained 6.6% to $172.15.</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) shares jumped 6.2% to $62.20.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/24/04/38376714/wall-streets-most-accurate-analysts-views-on-3-energy-stocks-with-over-3-dividend-yields">Wall Street&#8217;s Most Accurate Analysts&#8217; Views On 3 Energy Stocks With Over 3% Dividend Yields</a>

BGNE

CRML

MARA

RGEN

SMCI

HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday

HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.11 by 54.55 percent. This is a 88.89 percent increase over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $72.760 million which beat the analyst consensus estimate of $71.883 million by 1.22 percent. This is a 5.53 percent increase over sales of $68.946 million the same period last year.

HealthStream Q1 2024 GAAP EPS $0.17 Beats $0.11 Estimate, Sales $72.760M Beat $71.883M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; MainStreet Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNSB#NASDAQ">MNSB</a>) is projected to report quarterly earnings at $0.52 per share on revenue of $17.10 million.
&bull; Dynex Cap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DX#NYSE">DX</a>) is likely to report quarterly loss at $0.09 per share on revenue of $-570 thousand.
&bull; Zions Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) is projected to report quarterly earnings at $0.98 per share on revenue of $743.48 million.
&bull; Verizon Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) is likely to report quarterly earnings at $1.12 per share on revenue of $33.24 billion.
&bull; HBT Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBT#NASDAQ">HBT</a>) is projected to report quarterly earnings at $0.55 per share on revenue of $56.63 million.
&bull; AZZ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>) is projected to report quarterly earnings at $0.70 per share on revenue of $351.67 million.
&bull; Truist Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>) is estimated to report quarterly earnings at $0.80 per share on revenue of $5.70 billion.
&bull; Sify Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $149.30 million.
&bull; Washington Trust Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WASH#NASDAQ">WASH</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $31.50 million.
&bull; Bank of Hawaii (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOH#NYSE">BOH</a>) is estimated to report quarterly earnings at $0.87 per share on revenue of $160.21 million.
&bull; Kaspi.kz (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSPI#NASDAQ">KSPI</a>) is estimated to report earnings for its first quarter.
&bull; Albertsons Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $18.47 billion.
<h3>Companies Reporting After The Bell</h3>
&bull; Globe Life (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GL#NYSE">GL</a>) is expected to report quarterly earnings at $2.79 per share on revenue of $1.42 billion.
&bull; NBT Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTB#NASDAQ">NBTB</a>) is likely to report quarterly earnings at $0.68 per share on revenue of $135.32 million.
&bull; Simpson Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSD#NYSE">SSD</a>) is expected to report quarterly earnings at $1.92 per share on revenue of $549.85 million.
&bull; Crane (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CR#NYSE">CR</a>) is projected to report quarterly earnings at $1.12 per share on revenue of $546.38 million.
&bull; Hexcel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HXL#NYSE">HXL</a>) is likely to report quarterly earnings at $0.41 per share on revenue of $473.78 million.
&bull; RLI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLI#NYSE">RLI</a>) is expected to report quarterly earnings at $1.60 per share on revenue of $367.78 million.
&bull; Alexandria Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>) is likely to report quarterly earnings at $2.32 per share on revenue of $772.57 million.
&bull; Ameriprise Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>) is expected to report quarterly earnings at $8.20 per share on revenue of $4.12 billion.
&bull; Cleveland-Cliffs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) is projected to report quarterly earnings at $0.22 per share on revenue of $5.35 billion.
&bull; SAP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) is expected to report quarterly earnings at $1.11 per share on revenue of $8.56 billion.
&bull; AGNC Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGNC#NASDAQ">AGNC</a>) is expected to report quarterly earnings at $0.57 per share on revenue of $473.78 million.
&bull; Servisfirst Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SFBS#NYSE">SFBS</a>) is expected to report quarterly earnings at $0.88 per share on revenue of $109.10 million.
&bull; HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) is likely to report quarterly earnings at $0.11 per share on revenue of $72.02 million.
&bull; Lufax Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LU#NYSE">LU</a>) is estimated to report quarterly earnings at $0.12 per share on revenue of $1.02 billion.
&bull; Equity Lifestyle Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELS#NYSE">ELS</a>) is expected to report quarterly earnings at $0.49 per share on revenue of $387.14 million.
&bull; SmartFinancial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMBK#NYSE">SMBK</a>) is expected to report quarterly earnings at $0.41 per share on revenue of $39.14 million.
&bull; Trustco Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRST#NASDAQ">TRST</a>) is expected to report quarterly earnings at $0.60 per share on revenue of $43.13 million.
&bull; Independent Bank Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBTX#NASDAQ">IBTX</a>) is expected to report quarterly earnings at $0.59 per share on revenue of $121.39 million.
&bull; Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) is likely to report quarterly earnings at $2.46 per share on revenue of $512.58 million.
&bull; Cathay General (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATY#NASDAQ">CATY</a>) is likely to report quarterly earnings at $0.98 per share on revenue of $187.46 million.
&bull; Cadence Design Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) is likely to report quarterly earnings at $1.13 per share on revenue of $1.00 billion.
&bull; Brown &amp; Brown (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>) is estimated to report quarterly earnings at $1.06 per share on revenue of $1.22 billion.
&bull; Pinnacle Finl Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNFP#NASDAQ">PNFP</a>) is likely to report quarterly earnings at $1.56 per share on revenue of $423.19 million.
&bull; Cadence Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CADE#NYSE">CADE</a>) is expected to report quarterly earnings at $0.55 per share on revenue of $427.01 million.
&bull; SPDR ICE Preferred Securities ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSK#NYSE">PSK</a>) is estimated to report quarterly earnings at $0.18 per share on revenue of $129.00 million.
&bull; Enterprise Finl Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSC#NASDAQ">EFSC</a>) is expected to report quarterly earnings at $1.11 per share on revenue of $157.33 million.
&bull; RBB Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBB#NASDAQ">RBB</a>) is likely to report quarterly earnings at $0.34 per share on revenue of $27.65 million.
&bull; Calix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) is likely to report quarterly earnings at $0.20 per share on revenue of $228.14 million.
&bull; First Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRBA#NASDAQ">FRBA</a>) is estimated to report quarterly earnings at $0.42 per share on revenue of $31.41 million.
&bull; Packaging Corp of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>) is likely to report quarterly earnings at $1.62 per share on revenue of $1.90 billion.
&bull; Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) is likely to report quarterly earnings at $3.85 per share on revenue of $8.51 billion.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

AGNC

CADE

CATY

CDNS

EFSC

FRBA

IBTX

KSPI

MEDP

MNSB

NBTB

PNFP

SFBS

SIFY

SMBK

TRST

WASH

ZION

Earnings Scheduled For April 22, 2024

Dividends

HealthStream Increases Quarterly Dividend From $0.025 To $0.028

On February 19, 2024, the Board approved a quarterly cash dividend under the Company&#39;s dividend policy of&nbsp;$0.028&nbsp;per share, reflecting an increase of&nbsp;12%&nbsp;over the previous quarter&#39;s dividend of&nbsp;$0.025&nbsp;per share. The dividend is payable on March 22, 2024 to holders of record on March 11, 2024.

HealthStream Declared A Quarterly Cash Dividend Of $0.028/Share, An Increase Of 12% Over The Previous Quarter's Dividend Of $0.025/Share

Commenting on&nbsp;fourth quarter&nbsp;&amp; full-year 2023 results, Robert A. Frist, Jr., Chief Executive Officer, HealthStream, said, &quot;Our financial performance for full-year 2023 was strong. Compared to the prior year, in 2023 our revenues were up five percent, adjusted EBITDA was up&nbsp;15 percent, operating income was up&nbsp;29 percent, and net income was up&nbsp;26 percent. Based on our projections and&nbsp;guidance, I believe we will set new records again in 2024.&quot;
<table cellspacing="0">
<tbody>
<tr>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="10" rowspan="1">
Full-Year 2024&nbsp;Guidance
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="5" rowspan="1">
Low
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="4" rowspan="1">
High
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Revenue
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$
</td>
<td colspan="1" rowspan="1">
292.0
</td>
<td colspan="1" rowspan="1">
-
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$
</td>
<td colspan="1" rowspan="1">
296.0
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Adjusted EBITDA1
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$
</td>
<td colspan="1" rowspan="1">
64.5
</td>
<td colspan="1" rowspan="1">
-
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$
</td>
<td colspan="1" rowspan="1">
67.5
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Capital Expenditures
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$
</td>
<td colspan="1" rowspan="1">
28.0
</td>
<td colspan="1" rowspan="1">
-
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$
</td>
<td colspan="1" rowspan="1">
30.0
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
million
</td>
</tr>
</tbody>
</table>

HealthStream Expects 2024 Revenue Of $292M-$296M Vs. $296.97M Consensus, And Adjusted EBITDA Of $64.5M-$67.5M

HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0.10 by 50 percent. This is a 87.5 percent increase over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $70.58 million which missed the analyst consensus estimate of $71.79 million by 1.69 percent. This is a 2.98 percent increase over sales of $68.54 million the same period last year.

Reported Monday, HealthStream Q4 EPS $0.15 Beats $0.10 Estimate, Sales $70.58M Miss $71.79M Estimate

HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) reported its Q4 earnings results on Monday, February 19, 2024 at 04:30 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
HealthStream beat estimated earnings by 50.0%, reporting an EPS of $0.15 versus an estimate of $0.1.
Revenue was up $2.04 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.04 which was followed by a 14.86% increase in the share price the next day.
Here's a look at HealthStream's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.09</td>
<td>0.09</td>
<td>0.08</td>
<td>0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.13</td>
<td>0.13</td>
<td>0.12</td>
<td>0.08</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>70.66M</td>
<td>68.89M</td>
<td>68.26M</td>
<td>68.01M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>70.34M</td>
<td>69.20M</td>
<td>68.95M</td>
<td>68.54M</td>
</tr>
</tbody>
</table>

To track all earnings releases for HealthStream <a href="https://www.benzinga.com/quote/HSTM/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: HealthStream Q4 Earnings

Reports Q3 revenue $73.1M, consensus $73.53M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news....

HealthStream reports Q3 EPS 19c, consensus 12c

Consensus $292.37M. Raises FY24 adjusted EBITDA view to $66M-$67.5M from $64.5M-$67.5M. Published first on TheFly – the ultimate source for real-ti...

HealthStream cuts FY24 revenue view to $292M-$296M from $290M-$292M

An update from HealthStream ( ($HSTM) ) is now available. HealthStream reported strong financial results for Q3 2024, with a 3.9% increase in reven...

HealthStream Reports Strong Q3 2024 Financial Results

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp;&nbsp; HIGHER AFTER EARNINGS – Flexsteel Industries (FLXS)&n...

Closing Bell Movers: Medpace down 11% after cutting FY24 revenue guide

HealthStream, Inc. (HSTM) Q3 2024 Earnings Call Transcript

JMP Securities analyst Constantine Davides maintained a Hold rating on HealthStream (HSTM – Research Report) today. The company's shares closed yes...

JMP Securities Reaffirms Their Hold Rating on HealthStream (HSTM)

Barclays analyst Stephanie Davis maintained a Buy rating on HealthStream (HSTM – Research Report) today and set a price target of $34.00. The compa...

Barclays Sticks to Its Buy Rating for HealthStream (HSTM)

Barclays raised the firm's price target on HealthStream (HSTM) to $34 from $32 and keeps an Overweight rating on the shares. The firm says positive...

HealthStream price target raised to $34 from $32 at Barclays

Barrington analyst Vincent Colicchio has maintained their neutral stance on HSTM stock, giving a Hold rating today. Vincent Colicchio has given his...

Balanced Outlook: Hold Rating Amid Strong Revenue Growth and Cautious Valuation

Miller-Howard Small Cap Dividend Q3 2024 Commentary

ACIW

ADMA

ALSN

AMKR

ASPN

BOOM

CAKE

CHRD

CNOBP

CRCQW

FELE

FLXS

HWKN

IDCC

IRTC

KLIC

MOVAA

NMRK

OASPW

PGNY

SHLS

SLVM

WLLAW

WLLBW

Press Releases

HealthStream First Quarter 2024 Earnings Conference Call Announcement

HealthStream Announces First Quarter 2024 Results

HealthStream Second Quarter 2024 Earnings Conference Call Announcement

HealthStream Announces Second Quarter 2024 Results

HealthStream Announces Three Innovations for Privileging, Health Plan Credentialing, and Provider Data Management

HealthStream Third Quarter 2024 Earnings Conference Call Announcement

HealthStream Announces Third Quarter 2024 Results

HealthStream Completes Two Strategic Acquisitions, Expanding its Clinical Rotations Offering for Students, Schools, and Healthcare Organizations

HealthStream Launches HealthStream Learning Experience™ (HLX) Application, Powering Extended Workforce Development Capabilities With an AI-First Approach

HealthStream and American Red Cross Expand Their Market-Leading Resuscitation Suite Portfolio With New Neonatal Advanced Life Support Program

Comments

HealthStream

Noticias

Últimas noticias sobre HealthStream (NASDAQ:HSTM) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL